BenevolentAI Investor Conference Presentation Deck
BEN-8744 Phase la study overview
Study objectives: To assess the safety and tolerability of single and multiple oral doses, and the effect of food
on pharmacokinetic profile, of BEN-8744 in healthy volunteer subjects
Study conducted with healthy adult volunteers (18-65 y/o) at a phase 1 unit (HMR) in London, UK
Part A - SAD
Part B - Food Effect
Part C - MAD
●
4 of upto 6 groups of healthy
volunteers dosed @ 2mg, 6mg,
20mg and 60mg
8 subjects per group: (6:2)
Single oral doses of BEN-8744
administered in fasted state
Monitored up to 72h after
dosing, with follow up 7 days
after inpatient stay
Upto 2 groups of healthy
volunteers.
. Scheduled 11th Dec
●
6 subjects per group: 6 active
• Crossover design with 2 sessions
per subject, 7 days apart
o One dose BEN-8744 fasted
o One dose BEN-8744 after
high fat meal
●
BenevolentAl Proprietary
8 subjects per group: (6:2)
●
●
First of upto 3 groups of healthy
volunteers dosed
●
Daily (BID) oral doses of
BEN-8744 for 14 days
Monitored up to 72h after
dosing, with follow up 7 days
after inpatient stay
Study initiated in August 2023, topline data expected Q1 2024
Benevolent 18View entire presentation